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Abstract
Current anti-VEGF drugs for patients with diabetic retinopathy suffer from short residence
time in the vitreous of the eye. In order to maintain biologically effective doses of drug for
inhibiting retinal neovascularization, patients are required to receive regular monthly injec-
tions of drug, which often results in low patient compliance and progression of the disease.
To improve the intravitreal residence time of anti-VEGF drugs, we have synthesized multi-
valent bioconjugates of an anti-VEGF protein, soluble fms-like tyrosine kinase-1 (sFlt) that
is covalently grafted to chains of hyaluronic acid (HyA), conjugates that are termed mvsFlt.
Using a mouse corneal angiogenesis assay, we demonstrate that covalent conjugation to
HyA chains does not decrease the bioactivity of sFlt and that mvsFlt is equivalent to sFlt at
inhibiting corneal angiogenesis. In a rat vitreous model, we observed that mvsFlt had signifi-
cantly increased intravitreal residence time compared to the unconjugated sFlt after 2 days.
The calculated intravitreal half-lives for sFlt and mvsFlt were 3.3 and 35 hours, respectively.
Furthermore, we show that mvsFlt is more effective than the unconjugated form at inhibiting
retinal neovascularization in an oxygen-induced retinopathy model, an effect that is most
likely due to the longer half-life of mvsFlt in the vitreous. Taken together, our results indicate
that conjugation of sFlt to HyA does not affect its affinity for VEGF and this conjugation sig-
nificantly improves drug half-life. These in vivo results suggest that our strategy of multiva-
lent conjugation could substantially improve upon drug half-life, and thus the efficacy of
currently available drugs that are used in diseases such as diabetic retinopathy, thereby
improving patient quality of life.
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Introduction
Diabetes affects 285 million adults worldwide, which accounts for 6.4% of the world’s popula-
tion. This number is expected to increase to 439 million people by 2030 [1]. In the United
States alone, 25.8 million people have diabetes and it is estimated that another 57 million peo-
ple are considered pre-diabetic as a result of abnormally high blood glucose levels resulting
from poor diet. Diabetic retinopathy is one of the most debilitating consequences of diabetes
and is currently the leading cause of blindness among individuals aged 20–74 [2–4].
In the development of diabetic retinopathy, hypoxic neurons upregulate growth factors that
drive retinal angiogenesis, a process primarily mediated by vascular endothelial growth factor
(VEGF) [5–7]. Newly formed blood vessels have loose cell-cell junctions, causing macular
edema and pooling of blood, which leads to areas of vision loss. Anti-VEGF therapeutics such
as Lucentis (ranibizumab, Genentech, 48 kDa humanized antibody fragment), Avastin (bevaci-
zumab, Genentech, a 150 kDa humanized antibody) and Eylea (aflibercept, Regeneron, a 110
kDa VEGF-receptor fusion protein) are the clinically used drugs for treating diabetic retinopa-
thy in the clinic. However, these therapeutics suffer from short drug half-lives as a result of
small molecular size and single injections of these drugs provide limited therapeutic effect over
a finite period of time [8]. Consequently, low levels of patient compliance significantly limit the
effect of these drugs to maintain visual acuity [9,10]. Therefore, the development of new drug
delivery approaches is necessary to facilitate increased drug residence time within the vitreous.
Such approaches will help to reduce the frequency at which patients are required to receive
injections thereby improving quality of life as well as long term visual potential.
We have developed a novel multivalent drug technology platform that allows for the long-
term delivery of anti-VEGF drugs into the vitreous. Using a naturally occurring biopolymer,
hyaluronic acid (HyA) we synthesized drug multivalent conjugates by chemically conjugating
sFlt (soluble fms-like tyrosine kinase-1 [11]), an anti-VEGF protein, to the biopolymer chain
thereby significantly increasing the overall drug size. We have shown previously that these anti-
VEGF multivalent conjugates, mvsFlt, maintain their ability to bind VEGF and inhibit endothe-
lial cell proliferation, migration and tube formation in vitro. Furthermore, conjugation of sFlt to
HyA significantly enhanced retention within in vitromodels of the vitreous and protected sFlt
from protease degradation by matrix metalloproteinase-7, an enzyme that specifically degrades
sFlt [12]. The aim of this study was therefore to evaluate the in vivo activity of the mvsFlt conju-
gate. We used a corneal angiogenesis assay as an initial screen for examining the effect of HyA
conjugation on sFlt bioactivity and then investigated the half-life of mvsFlt in the rat vitreous in
order to determine how HyA conjugation affected residence time of sFlt. Finally, we employed a
rat oxygen-induced retinopathy (OIR) model to examine both bioactivity and the effect of
increased mvsFlt half-life on retinal angiogenesis. The results from this study suggest our conju-
gation technology may have far reaching impacts on the development of pharmaceuticals with
longer half-lives in the vitreous not only for treating diabetic retinopathy but also for retinal
neovascular diseases such as wet age-related macular degeneration (wet-AMD).
Materials and Methods
2.1. Expression of Soluble Flt-1 Receptor
The sFlt sequence for the first 3 Ig-like extracellular domains of sFlt-1 was cloned as previously
described [13] into the pFastBac1 plasmid (Life Technologies) and then transformed into
DH10Bac E.coli, which were plated on triple antibiotic plates containing kanamycin (50 μg/
mL, Sigma Aldrich), gentamicin (7 μg/mL, Sigma Aldrich), tetracycline (10 μg/mL, Sigma
Aldrich), IPTG (40 μg/mL, Sigma Aldrich) and Bluo-gal (100 μg/mL, Thermo Fisher
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Scientific). The sFlt gene-containing bacmid was isolated from DH10Bac E.coli (Life Technolo-
gies) and transfected into SF9 insect cells for virus production (provided by the Tissue Culture
Facility, UC Berkeley). Virus was then used to infect High Five insect cells (provided by the Tis-
sue Culture Facility, UC Berkeley) to induce sFlt protein expression. After 3 days, protein was
purified from the supernatant using Ni-NTA agarose beads (Qiagen Laboratories). Recombi-
nant sFlt was eluted from the Ni-NTA beads using an imidazole (Sigma Aldrich) gradient and
then concentrated and buffer exchanged with 10% glycerol/PBS using Amicon Ultra-15mL
Centrifugal devices (EMDMillipore). The protein solution was sterile filtered and the concen-
tration was determined by BCA assay (Thermo Fisher Scientific). The molecular weight of sFlt
was determined from a 4–20% gradient SDS-PAGE gel and estimated to be 50 kDa [12].
2.2 mvsFlt Conjugate Synthesis
Conjugation of sFlt to HyA was carried out according to the schematic in Fig 1, and as
described previously ([12,14–16]. To make thiol-reactive HyA intermediates, 3,30-N-(ε-malei-
midocaproic acid) hydrazide (EMCH, Pierce, 1.2 mg/mL), 1-hydroxybenzotriazole hydrate
(HOBt, Sigma, 0.3mg/mL) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochlo-
ride (EDC, Pierce, 10 mg/mL) were added to a 3 mg/ml solution of 650 kDa HyA (Lifecore Bio-
technology) in 0.1 M 2-(N-morpholino) ethanesulphonic acid (MES) (Sigma) buffer (pH 6.5)
and allowed to react at 4°C for 4 h. The solution was then dialyzed into pH 7.0 phosphate-buff-
ered saline (PBS) containing 10% glycerol. Recombinant sFlt was treated with 2-iminothiolane
at 10 molar excess to create thiol groups for conjugation to the maleimide group on EMCH.
Activated HyA-EMCH was then added to sFlt at a 1:10 molar ratio (HyA to sFlt) and allowed
to react at 4°C overnight to synthesize the final mvsFlt conjugate. The mvsFlt conjugate was
dialyzed with 100 kDa molecular weight cut-off (MWCO) Float-A-Lyzer G2 (Spectrum Labs)
in pH 7.0 PBS exhaustively to remove unreacted sFlt. The concentration of mvsFlt was mea-
sured using a BCA assay.
2.3 Corneal Angiogenesis Assay
All experiments were performed with a total of 32 wild-type 7 to 12-week old male and female
littermate FVB/n mice. Mice were maintained under pathogen-free conditions in the UCSF
barrier facility and experiments conducted in accordance with procedures approved by the
UCSF Institutional Animal Care and Use Committee (IACUC). All experiments were
approved by the UCSF IACUC prior to work. Mice were anesthetized by isofluorane inhalation
(Abbott Laboratories, Abbott Park, IL), 10mg/kg carprofren (Sigma, St. Louis, MO), and by
topical application of 0.5% Proparacaine (Bausch & Lomb, Rochester, NY) placed on the cor-
nea. An alkaline burn was created by applying filter paper 2.5 mm in diameter soaked in 0.1N
NaOH (Sigma Aldrich) for 30 seconds to the central cornea followed by rinsing with 250 μL of
PBS. After the chemical burn treatment, topical 0.5% proparacaine was added to the cornea for
anesthesia. Mice were administered 5 μL subconjunctival injections with sFlt (150 μg/ml),
mvsFlt (150 μg/ml), or PBS at day 1 and day 3 after burn. Ten days after treatment, eyes were
enucleated and the corneas were dissected and fixed in 4% paraformaldehyde overnight at 4°C.
Corneas were blocked with 3% BSA and stained with DAPI, rabbit anti-mouse CD31 primary
antibody (Santa Cruz Biotechnology) and goat anti-rabbit Alexa Fluor 488 secondary antibody
(Life Technologies) for visualization and quantification of blood vessels. Corneas were cut into
quadrants and flat-mounted onto glass slides using Fluoromount Mounting Medium (Sigma
Aldrich). Imaging was carried out with an automated slide scanner, Zeiss Axioscan Z1 (Zeiss
Instruments). Corneal blood vessel coverage was quantified using NIH ImageJ software by
comparing the total cornea area to the corneal vascularized area.
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2.4 Determination of mvsFlt Intravitreal Residence Time
All residence time experiments were performed on 8-week old Brown Norway rats (24 rats total
with 12 in each group) obtained from Charles River Laboratories and treated in accordance
with protocols approved by the Institutional Animal Care and Use Committee at UC Berkeley.
All experiments were approved by the UC Berkeley IACUC prior to work. Rats were anesthe-
tized using a mixture of ketamine and xylazine (50 mg and 10 mg/kg body weight, respectively)
for the surgical procedure. Eyes were injected intravitreally 1 mm behind the limbus with 5 μL
of PBS, sFlt or mvsFlt at 1 mg/mL using a 30-gauge Hamilton syringe and monitored daily for
Fig 1. Synthesis of mvsFlt schematic.mvsFlt bioconjugates were synthesized using a 3-step reaction in
which HyA was reacted with EDC and EMCH to create a thiol reactive HyA-EMCH intermediate. sFlt was
then treated with 2-iminothiolane and reacted with the HyA-EMCH intermediate for the synthesis of the final
mvsFlt bioconjugate.
doi:10.1371/journal.pone.0155990.g001
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signs of inflammation. This concentration was selected to maximize fluorescence in the vitreous
and remain in the detection limit of the fluorometer after 48 hours. Rats were sacrificed with
CO2 asphyxiation in groups at 0, 4, 12, 24 and 48 hours post injection and eyes were immedi-
ately enucleated and placed on dry ice. Frozen vitreous was then extracted from the eye and
immersed in 100 μL of RIPA buffer. After shaking on ice for 2 hours, each vitreous sample was
homogenized with a Tissue Tearor (Bio Spec Products, Inc.) and the fluorescence measured
using a fluorometer (Molecular Devices). Quantification was carried out by normalizing the
fluorescence of vitreous samples to the 0 hour vitreous fluorescence readings within their
respective group. The half-lives of sFlt and mvsFlt were calculated according to Eq 1:
Ct ¼ C0ekt ð1Þ
Where Ct is the concentration at time t, C0 is the initial concentration and k is the elimination
constant given by Eq 2:
k ¼ logð2Þ
t1=2
ð2Þ
Where t1/2 is the drug half-life. The values used for calculating t1/2 were based on data from the
48-hour time point.
2.5 OIR Rat Angiogenesis Model
Pregnant Brown Norway rats were obtained from Charles River Laboratories. All the animal
experiments were performed in compliance with the ARVO statement for the Use of Animals
in Ophthalmic and Vision Research and approved by the University of Oklahoma Institutional
Animal Care and Use Committee. Newborn pups were assigned to PBS, sFlt or mvsFlt treat-
ment groups (6 rat pups in each group). Light was cycled on a 12 hour on, 12 hour off schedule
and room temperature was maintained at approximately 21C. Rat pups were exposed to hyper-
oxia (75% O2) from postnatal day 7 (P7) to P12. The oxygen-treated rats were housed in an
incubator connected to an Oxycler Model A4 (Redfield, NY) with oxygen and nitrogen, allow-
ing for adjustment of oxygen concentration to 75%±2%. The rats were placed in the oxygen
chamber with enough food and water to sustain them for 5 days. On P12, the animals were
returned to room air and administered intravitreal injections with 2 μL per eye of PBS, sFlt or
mvsFlt at 150 μg/mL. Rats at P17 were anesthetized and perfused with high-molecular weight
FITC-dextran (2 MDa; Sigma-Aldrich, St. Louis MO) as described by Smith et al [17]. Retinas
were dissected and flat-mounted and the vasculature was imaged using a fluorescence micro-
scope (CKX41; Olympus). Vascular coverage at P17 was quantified using NIH ImageJ by com-
paring the total retinal area to the area of vascularization.
2.6 Statistical Analysis
Values are expressed as means ± standard deviations (SD). Statistical analysis was performed
with two-tailed t-tests to compare mean values. One-way (with Tukey post-hoc analysis) and
two-way ANOVA (with Bonferroni posttest) were also used to compare treatment groups in
the quantitative measurements where appropriate (Prism, GraphPad Software). A P-value of
less than 0.05 was considered to be statistically significant.
Results
3.1 sFlt and mvsFlt equally inhibit corneal angiogenesis
The chemical injury-based corneal angiogenesis model was used to determine whether conju-
gation of sFlt to HyA reduced the bioactivity of mvsFlt to in comparison to sFlt in vivo. Ten
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days-post corneal injury, all mice treated with sFlt and mvsFlt displayed similar inhibitory pro-
files of corneal angiogenesis (Fig 2). Corneas treated with PBS had 28.8±11.5% blood vessel
coverage in contrast to corneas treated with sFlt and mvsFlt, which had 12.8±3.8% and 15.8
±7.1% vascular coverage, respectively.
3.2 mvsFlt has significantly longer residence time in vitreous
We initially confirmed that the vitreous of Brown Norway rats could be used to determine
intravitreal residence time of different sized molecules using fluorescently tagged dextrans of
varying sizes (S1 Fig). Differences in residence time between sFlt and mvsFlt were immediately
apparent beginning at 4 hours where only 18.2±7.3% of sFlt remained compared to 105.8
±9.8% of mvsFlt (Fig 3). By 12 hours, only 2.6±1.9% of sFlt remained detectable compared to
62.9±14.1% of mvsFlt. By 2 days post injection, sFlt was almost undetectable (1.2±0.5%)
whereas 66.2±28.6% of mvsFlt remained in the vitreous. The half-life of sFlt in the vitreous was
calculated using Eqs 1 and 2 to be 3.3 hours compared to 35 hours for mvsFlt.
3.3 mvsFlt is a more potent inhibitor of retinal neovascularization
We next used an OIR model of retinal angiogenesis to examine the effect of HyA conjugation
with sFlt on the inhibition of retinal angiogenesis. This short-term model allowed us to also
Fig 2. sFlt andmvsFlt equally inhibit corneal angiogenesis. A) Schematic depicting methods utilized for carrying
out corneal burn model. Mice were treated twice with 5μl of PBS, sFlt or mvsFlt at day 1 and 3 following the chemical
burn. B) Representative images of eyes treated with PBS, sFlt and mvsFlt. CD31 positive (green) staining of corneal
blood vessels. C) Quantification of corneal angiogenesis at day 10 following treatment. One-way ANOVA gives p value
**<0.01 (n.s.- not significant; *p<0.05; **p<0.01). Scale bars correspond to 20 μm.
doi:10.1371/journal.pone.0155990.g002
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indirectly examine the effect of mvsFlt half-life on prolonged angiogenesis inhibition. Neovas-
cular coverage was calculated by comparing the area of vascular coverage to total retinal area.
After 5 days of treatment, retinal vascular coverage of PBS-injected eyes was 84.3±3.8% and
retinas treated with intravitreal injections of sFlt were 85.4±6.1%. In contrast, retinas from rats
treated with intravitreal injections of mvsFlt were significantly lower and had 72.9±3.4% retinal
vascular coverage (Fig 4).
Fig 3. mvsFlt has longer residence time in the rat vitreous. A) Schematic depicting methods used to
determine the half-life of fluorescently tagged sFlt and mvsFlt in the rat vitreous. The vitreous was injected with
5μl of Alexa Fluor 488-tagged sFlt or mvsFlt. After 0, 4, 12, 24, and 48 hours, the rats were sacrificed and their
eyes were enucleated and frozen for analysis. The vitreous was then removed, immersed in RIPA buffer and
homogenized for subsequent fluorescence measurements. B) Conjugation to HyA significantly improves
residence time of sFlt in the vitreous after 48 hours in comparison to sFlt. Results are expressed as mean ±SD
(*p<0.05, **p<0.01, ***p<0.001). * indicates a difference between the mvsFlt and sFlt at the given time point.
Two-way ANOVA gives p-value ***<0.001.
doi:10.1371/journal.pone.0155990.g003
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Discussion
The overall goal of this study was to determine whether increasing sFlt molecular size through
conjugation to HyA would increase drug half-life in the vitreous and to investigate the ability
of the multivalent sFlt bioconjugate to inhibit in vivo angiogenesis. In contrast to other drugs
that are currently used for treating diabetic retinopathy that suffer from short half-lives, we
have developed large macromolecules of multivalent protein bioconjugates that maintain their
ability in inhibiting VEGF-driven angiogenesis in vivo and show significantly longer residence
time in the vitreous.
Previously, we described a chemical scheme for creating multivalent protein bioconjugates
of HyA and the anti-VEGF molecule, sFlt as shown in Fig 1 [12]. We were able to make several
mvsFlt bioconjugates of varying molecular weights and protein valencies, all of which were
equally able to inhibit VEGF in several in vitro assays of angiogenesis. We also demonstrated
that conjugation of sFlt to HyA shielded the protein from protease degradation with a matrix
Fig 4. mvsFlt inhibits retinal angiogenesis. A) Schematic showing methods used for carrying out the OIR model. Newborn rat pups were housed in
normoxic conditions (21% oxygen, room air) from post-natal day (P) 0–7 to allow for normal retinal vasculature development and then transferred to
hyperoxic conditions from P7-P12, which induces vessel pruning. At P13, the pups are transferred back into normoxic conditions and treated with 2 μl of
PBS, sFlt or mvsFlt and sacrificed at P17. B) Representative images of retinas treated with PBS, sFlt and mvsFlt. Prior to sacrifice, rat pups were injected
with fluorescently-tagged 2 MDa dextran to visualize vessel coverage. Scale bar corresponds to 250 μm. Dashed boxes magnify that portion of tissue (scale
bar corresponds to 100 μm). C) Quantified retinal vascularization after 5 days of treatment. Percent retinal vascularization was calculated by comparing the
area of vascularization to the total retinal area in the image. One-way ANOVA gives p-value***<0.001 (n.s.-not significant; **p<0.01).
doi:10.1371/journal.pone.0155990.g004
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metalloproteinase that is specific to sFlt, MMP-7 [18]. We created an in vitromodel of the vit-
reous using crosslinked HyA hydrogels to examine the effect of HyA conjugation of sFlt diffu-
sion. We found that low molecular weight mvsFlt (300 kDa), which had hydrodynamic
diameter of 123.9 nm (±23.1 nm), had very similar diffusion profiles to sFlt whereas higher
molecular weight mvsFlt (650 kDa and 1 MDa mvsFlt) diffused significantly slower. We chose
to investigate the 650 kDa bioconjugate for its activity in vivo.
In this study, we used several different in vivo animal models for addressing the following
three questions: 1) does the conjugation of sFlt to HyA affect the ability of sFlt to inhibit
VEGF-driven angiogenesis; 2) does increasing the overall molecular size of sFlt lead to pro-
longed intravitreal half-life; and 3) does increasing intravitreal half-life prolong the inhibitory
profile of sFlt. To answer our first question, we used a corneal angiogenesis assay as a method
to easily visualize the effect of sFlt and mvsFlt on inhibition of angiogenesis. This assay is an
excellent model for studying in vivo angiogenesis due to ease of vessel visualization on the
physiologically avascular and transparent cornea, which rapidly vascularizes upon stimulation
with a chemical burn or injury [19,20]. Results from the corneal angiogenesis assay indicated
that subconjunctivally administered sFlt and mvsFlt equally inhibited VEGF-driven angiogene-
sis as shown in Fig 2. We did not anticipate a difference in angiogenesis inhibition between the
conjugated and unconjugated protein due to the nature of clearance mechanisms in the cornea
and the subconjunctival space [21]. Following injection of drugs into the subconjunctival
space, drugs are rapidly cleared into systemic blood circulation via an extensive capillary net-
work that is able to absorb large hydrophilic substances such as sFlt and mvsFlt due to the pres-
ence and abundance of large pores in the vascular epithelium [22,23]. We anticipated that the
large pores in the vascular epithelium would clear both sFlt and mvsFlt at similar rates despite
their significantly different sizes, which our results validated.
To address our second question, we examined the direct effect of HyA conjugation on the
half-life of mvsFlt in the rat vitreous. We initially validated this model using fluorescently
tagged dextrans and found that greater than 94% of the 40 kDa and 2 MDa dextrans were
cleared within 48 hours (S1 Fig). Based on this data, we chose to examine the following 5 time
points for examining the half-life of mvsFlt: 0, 4, 12, 24 and 48 hours. Significant differences in
residence time were observed between sFlt and mvsFlt beginning at 4 hours and sustained until
the end of the study at 48 hours as demonstrated in Fig 3. The half-lives of sFlt and mvsFlt
were calculated according to Eqs 1 and 2 and were determined to be 3.3 and 35 hours, respec-
tively. Conjugation to HyA therefore increased the half-life of sFlt by approximately 10-fold,
an effect seldom seen in the literature, outside of implant technologies. In comparison, lipo-
somal delivery of bevacizumab increased the drug half-life by 5 times [24] but this approach
presents several challenges including complexity of synthesis, aggregation of liposomes and
blurring of vision. PEGylation is another approach to improve the half-life of drugs. PEGyla-
tion of the aptamer in pegaptanib improved its half-life by 2.5 fold from 4.2 days [25] to 10±4
days [26].
The OIR model [27,28] enabled us to examine retinal neovascularization with the added
advantage of also indirectly investigating the effect of conjugation on prolonged inhibition due
to increased residence time mvsFlt conjugate in the vitreous, which helped us address our third
and final question. In contrast to the cornea where conjugation does not show a significant
advantage, the vitreous is a tissue where clearance mechanisms are highly dependent on molec-
ular size [29,30]. Due to its increased hydrodynamic diameter, we anticipated that the mvsFlt
conjugate would have a longer half-life in the vitreous and result in a prolonged duration of
angiogenesis inhibition. The mvsFlt conjugate showed superior inhibition of retinal angiogene-
sis in this model in comparison to sFlt, which did not inhibit angiogenesis in comparison to the
PBS control (Fig 4).
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We believe that this difference in inhibition of retinal angiogenesis is primarily due to clear-
ance of the sFlt from the vitreous more rapidly in comparison to mvsFlt, resulting in ineffective
angiogenesis inhibition. At the time of injection, both sFlt and mvsFlt have similar concentra-
tions in the vitreous (Fig 5A). Over time, sFlt is small enough to be cleared from the vitreous
leaving much lower concentrations of drug (Fig 5B, top). This allows for an increase in the
intravitreal VEGF concentration, which induces angiogenesis. In contrast, mvsFlt has a much
longer intravitreal residence time and is thus able to act as a sponge for VEGF over time (Fig
5B, bottom), inhibiting angiogenesis and maintaining the basal level of vascularization in the
retina. The time over which this occurs is highly dependent on the animal model being used.
Lucentis, which is similar in size to sFlt and is also a protein therapeutic, has an intravitreal
half-life of 2.9 days in rabbits [31] and 2.6 days in rhesus monkeys [32]. The disparity in the
half-lives of our compounds and those of therapeutics tested in rabbit and monkey models is
most likely due to anatomical differences in ocular globe size and differences in the rate of vit-
reous turnover between species. We anticipate that the unconjugated sFlt would perform simi-
larly to Lucentis in rabbit and monkey models whereas the mvsFlt would likely show
significant improvement in half-life over currently used therapeutics based on our preliminary
studies shown in Fig 3.
Comparable approaches have been taken to increasing intravitreal half-lives of anti-VEGF
compounds such as the sFlt peptide presented by Oh et al. [33,34]. The approach involves the
formation of micelles based on the hydrophobic nature of the sFlt-1 peptide and hydrophilicity
of HyA. The use of these types of self-assembling nanoparticles in intravitreal applications has
been documented in the past and often results in particle aggregation and blurring of vision
due to particle instability [35,36]. The sFlt-1 protein fragment we developed is also significantly
more active than the peptides described by Oh et al. We have performed similar VEGF165 ELI-
SAs and our calculations indicate that the IC50 for our mvsFlt conjugates ranges between 50–
150 pM, approximately 4 orders of magnitude more potent than the HyA-sFlt-1 peptides. Fur-
thermore, due to the simplicity in the approach we outline, we are able to apply this technique
Fig 5. Schematic demonstrating the proposedmechanism of mvsFlt action. A) sFlt (red, unconjugated) and mvsFlt (red
conjugated blue chain of HyA) are injected into a diabetic retina where there is a high concentration of VEGF (green circles). B)
After a given time, t, the majority of the sFlt has been cleared from the vitreous and VEGF is thus able to induce blood vessel
growth. mvsFlt has a longer residence time in the vitreous and is able to bind and inhibit VEGF over much longer periods of
time, leading to prolonged inhibition of retinal angiogenesis.
doi:10.1371/journal.pone.0155990.g005
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to many anti-VEGF proteins including clinically approved Avastin and Lucentis. In our
approach we use sFlt-1 as a model protein to demonstrate efficacy of a protein-based multiva-
lent conjugate. We believe that similar results would be achieved with clinically approved pro-
tein-based therapeutics based on similarity in protein charge, size and activity.
The current approach to treating retinal neovascularization including diabetic retinopathy
is carried out through intravitreal injection through the sclera. Once injected into the vitreous,
drugs distribute through the vitreous in a charge and size dependent manner and are cleared
from the vitreous through two main routes: anterior and posterior elimination. Small mole-
cules are able to diffuse through the vitreous rapidly and have short half-lives whereas large
molecules have retarded diffusion that results in longer half-lives. Large, hydrophilic molecules
are able to passively diffuse through the vitreous, around the lens into the anterior chamber
and are cleared through the Schlemm’s canal or the uveoscleral outflow pathway. Due to the
large surface area of the retina, molecules capable of posterior clearance have significantly
lower half-lives in comparison to those eliminated through the anterior route [21,37].
The development of drugs with longer residence times for patients with diabetic retinopathy
has been in high demand with the increasing prevalence of diabetes in populations worldwide.
Currently used drugs have short half-lives in the vitreous due to small molecular size and thus
require patients to receive frequent intravitreal injections, leading to low patient compliance
and worsening of the disease. Clinically approved drugs Avastin, Lucentis, and Eylea have half-
lives of 7.4 [38], 6.7 [31,32], and 5 days [39,40], respectively and require patients to receive
injections every 4–6 weeks to maintain effective levels of intravitreal drug [8]. Several different
approaches have been taken to increase drug residence time in the vitreous for treating diseases
of the posterior segment, each with its own advantages and drawbacks. Intravitreal implants
have received much of the attention in intravitreal drug delivery over the last two decades and
have primarily been used for corticosteroid delivery in posterior uveitis, diabetic macular
edema (DME), and retinal vein occlusion. Implantable devices are able to deliver a constant
supply of drug over several months to several years. Several types of implants have been devel-
oped such as Iluvien [41], Ozurdex [42], and Retisert [43] and vary in degradability, duration
of effect, size, delivery method and composition. Despite being able to deliver drug over long
periods of time, implants often require surgical implantation and invasive removal of the
implant after the drug is depleted. Particulate systems such as liposomes and nanoparticles
have also emerged as a drug delivery option for treating retinal diseases. Although drug deliv-
ery with particulate systems provides stability for the entrapped drug and is more straightfor-
ward requiring minimally invasive intravitreal injections, this approach is accompanied by
several disadvantages including the formation of precipitate that blurs vision, increased pro-
duction cost and heterogeneity in formulation due to aggregation of particles [36,44]. PEGyla-
tion has also been employed to increase intravitreal half-life of drugs and is the core technology
behind Macugen, a PEGylated anti-VEGF aptamer (Bausch + Lomb). Although similar in the-
ory to our approach, PEGylation uses a synthetic polymer for conjugation to a single biological
molecule, which often results in significantly decreased drug bioactivity [45,46]. Furthermore,
PEGylation on the Macugen aptamer did not result in a drug with significantly longer half-live
compared to clinically available drugs, most likely due to the small size of polyethylene glycol
chain that employed [47].
In contrast to these approaches, we employed a multivalent conjugate approach with HyA,
a naturally occurring biopolymer found in high concentrations within the vitreous, and conju-
gated to it several molecules of sFlt, a potent anti-VEGF protein. HyA was chosen not only
based on its natural ubiquity within the eye and body but also due to its exceptionally low turn-
over rate within the vitreous, 30 days [48]. We have shown that conjugation of sFlt to HyA
does not negatively impact the ability of sFlt to bind and inhibit VEGF in vitro [12] or reduce
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its anti-angiogenic potency in vivo (Fig 2), effects that accompany the other conjugation tech-
nology, protein PEGylation. Furthermore, we demonstrated that conjugation to HyA signifi-
cantly improved the residence time of sFlt in the vitreous of the eye (Fig 3), which resulted in
prolonged inhibition of retinal angiogenesis (Fig 4). Given these promising results, we antici-
pate that the future clinical use of multivalent conjugates of sFlt may significantly increase the
intravitreal drug residence time and inhibit retinal angiogenesis over a longer period of time.
Due to the ease of synthesis and tunability in this approach, we believe that our conjugation
technology could be instrumental in improving the half-life of drugs in the human eye not only
for treating diabetic retinopathy but other diseases as well.
Supporting Information
S1 Fig. Higher molecular weight dextran displays longer residence time in vivo. A) Valida-
tion experiment demonstrating the effect of size on the retention of fluorescently tagged dex-
trans. The 2 MDa dextran (solid line) has significantly improved residence time over the 40
kDa (dashed line) over 48 hours. The half-life of the 40 kDa and the 2 MDa dextrans is 3.2 and
5 hours, respectively.  indicates a difference between the 40 kDa and 2 MDa dextran at the
given time point. Two-way ANOVA gives p-value <0.05 ( corresponds to a P-value less
than 0.01).
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